Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 2, 2011, Pages 497-505

  Huang, Shouqing ^a   Lin, Jianzh ^a   Guo, Na ^a   Zhang, Min ^b   Yun, Xia ^b   Liu, Song ^c   Zhou, Ji ^d   He, Ellen ^d   Skog, Sven ^d  

^a Fujian Chinese Tradition Medicine University   (China)

^b Purehealth Bio Tech Co Ltd   (China)

^c SSTK Ltd   (China)

^d Sino Swed Molecular Bio Medicine Research Institute   (China)

Author keywords

Health screening; Hyperplasia of breast; Malignancy; Premalignancy; Prostate benign hyperplasia (PBH); Serological thymidine kinase 1 (STK1)

Indexed keywords

EID: 79958791384     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Anderson BO, Calhoun KE, Rosen EL (2006). Evolving concepts in the management of lobular neoplasia. J Natl Compr Canc Netw, 4, 511-22.
2. Blair A, Purdue MP, Weisenburger DD, et al (2007). Chemical exposures and risk of chronic lymphocytic leukaemia. Br J Haematol, 139, 753-61.
3. Bodian CA, Perzin KH, Lattes R (1996). Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer, 78, 1024-34.
4. Broet P, Romain S, Daver A, et al (2001). Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol, 19, 2778-87.
5. Butler LM, Wu AH, Wang R, et al (2010). A vegetable-fruitsoy dietary pattern protects against breast cancer among postmenopausal Singapore Chinese women. Am J Clin Nutr, 91, 1013-9.
6. Cariati M, Purushotham AD (2008). Stem cells and breast cancer. Histopathology, 52, 99-107.
7. Carlsson L, Larsson A, Lindman H (2009). Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer. Ups J Med Sci, 114, 116-20.
8. Chan E, Nimnual AS (2010). Deregulation of the cell cycle by breast tumor kinase (Brk). Int J Cancer, DOI: 10.1002/ijc.25263.
9. Chen Z, Zhou H, Li S, et al (2008). Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours. Anticancer Res, 28, 3897-907.
10. Chen Y, Ying M, Chen Y, et al (2010). Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings. Int J Clin Oncol, 15, 359-68.
11. Cigna, Cigna Healthcare Coverage Position (2008). Markers for Diagnosis and Management of Cancer, Coverage Position Number 0172, 1-20.
12. Dingwei Y, Changling L (2007). Epidemiological trends of prostate cancer: retrospect and prospect. China Oncol, 17, 177-80.
13. Duan YS (2010). Women's diseases screening in 18,073 persons. Chinese Rural Hlth Service Administration, 30, 476-8.
14. Hallek M, Wanders L, Strohmeyer S, et al (1992). Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol, 65, 1-5.
15. He Q, Zhang PA, Li HX, et al (2005). A comparable study between the concentration and the activity of serum thymdine kinase (S-TK) in human solid tumors. Oncology Report, 14, 1013-9.
16. He Q, Fornander T, Johansson H, et al (2006). Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res, 26, 4753-9.
17. He E, Xu XH, Guan H, et al (2010). Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma. Nucleosides Nucleotides Nucleic Acids, 29, 352-8.
18. Hu ZH (2006). Hyperplasia breast disease and breast cancer. Chinese Hydropower Medicine, 1, 60-1.
19. Im A, Vogel VG, Ahrendt G, et al (2009). Urinary estrogen metabolites in women at high risk for breast cancer. Carcinogenesis, 30, 1532-5.
20. Kallander CF, Simonsson B, Hagberg H (1984). Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer, 54, 2450-5.
21. Letocha H, Eklöv S, Gronowitz S, et al (1996). Deoxythymidine kinase in the staging of prostatic adenocarcinoma. Prostate, 29, 15-9.
22. Li HX, Zhang S, Lei DS, et al (2005). Serum thymidine kinase 1 (STK1) is a prognostic and monitoring factor in patients with non-small-cell lung cancer. Oncol Rep, 13, 145-9.
23. Li S, Wang Y, Ren P (2008). The Relationship between Pathological Grade of Incidental Prostate Carcinoma and Patient Survival. Chinese Clin Oncol, 35, 68-70.
24. Li Z, Wang Y, He J, et al (2010). Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas. Eur J Cancer Prev, 19, 313-8.
25. Luo P, He E, Eriksson S, et al (2009). Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker. Eur J Cancer Prev, 18, 220-4.
26. Luo P, Wang N, He E, et al (2010). The proliferation marker thymidine kinase 1 level is high in normal kidney tubule cells compared to other normal and malignant renal cells. Pathol Oncol Res, 16, 277-83.
27. Munch-Petersen B (2010). Enzymatic regulation of cytosolic thymidine kinase 1 and mitochondrial thymidine kinase 2: a mini review. Nucleosides Nucleotides Nucleic Acids, 29, 363-9.
28. Nielsen FH (2010). Magnesium, inflammation, and obesity in chronic disease. Nutr Rev, 68, 333-40.
29. O'Neill KL, Buckwalter MR, Murray BK (2001). Thymidine kinase: diagnostic and prognostic potential. Expert Rev Mol Diagn, 1, 428-33.
30. Page DL, Kidd TE Jr, Dupont WD, et al (1991). Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol, 22, 1232-9.
31. Pan ZL, Ji XY, Shi YM, et al (2010). Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapytreated non-Hodgkin's lymphoma patients. J Cancer Res Clin Oncol, 136, 1193-9.
32. Pang J (2010). Hyperplasia breast disease are suffered in woman. Zhonlaonnian Baolian, 2, 12-3.
33. Parr CL, Batty GD, Lam TH, Barzi F, et al (2010). Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424 519 participants. Lancet Oncol, 11, 741-52.
34. Pissaia A, Bernard D, Scatton O, et al (2009). Significance of Serum Tumor Markers Carcinoembryonic Antigen 19-9, CA 125, and CA 15-3 in Pre-Orthotopic Liver Transplantation Evaluation. Transplant Proc, 41, 682-4.
35. Qian DZ, Huang CY, O'Brien CA, et al (2009). Prostate cancerassociated gene expression alterations determined from needle biopsies. Clin Cancer Res, 15, 3135-42.
36. Shah R, Mucci NR, Amin A, et al (2001). Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol, 158, 1767-73.
37. Topolcan O, Holubec L Jr (2008). The role of thymidine kinase in cancer diseases. Expert Opin Med Diagn, 2, 129-41.
38. Underwood JCE (2004). General and Systematic Pathology. London, Churchill Livingstone, pp 46: 201-222, 223-262, 370-375, 410-432.
39. Vogel VG (2004). Atypia in the assessment of breast cancer risk: implications for management. Diag Cytopathol, 30, 151-7.
40. Wang G, Zhou L, Na YQ (2005). Retrospective analysis of incidental prostatic carcinoma after surgery of BPH: ten years' results. Chin J Urol, 26, 117-9.
41. Wang T, Bian CD, Yuan T, et al (2008). Guo Yaping, Liao GuoQiang Liao, Cao Chenghua Chinise analysis of 51 cases of incidental prostatic carcinoma. Shanghai Med J, 31, 110-2.
42. Wolin KY, Carson K, Colditz GA (2010). Obesity and cancer. Oncologist, 15, 556-65.
43. Wu CJ, Yang RJ, Zhou J, et al (2003). Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods, 277, 157-69.
44. Xu XH, Zhang YM, Shu XH, et al (2008). Serological thymidine kinase 1 reflects progression of pre-malignant and malignant tumours during therapy. Molecular Medicine Report, 1, 705-12.
45. Xu W, Cao X, Miao KR, et al (2009). Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors. Int J Hematol, 90, 205-11.
46. Yang L, Parkin DM, Ferlay J, et al (2005). Estimates of Cancer Incidence in China for 2000 and Projections for 2005. Cancer Epidemiol Biomarkers Prev, 14, 243-50.
47. Yu YN, Yip GW, Tan PH, et al (2010). Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle. Int J Oncol, 37, 483-92.
48. Zhang J, Jia Q, Zou S, et al (2006). Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncology Report, 15, 455-61.
49. Zhang J, Iao C, We IF (2008). Serum thymidine kinase 1: a prolifera tion marker for neoplasms immunologic monitoring of elderly people. Modern Oncol Med, 5, 831-2.
50. Zhang XH, Yang JR, Fu XY, et al (2010). The significance of serum thymidine kinase 1 for the risk screening of cancer development in pre-cancerous diseases. J Chinese Hlth Management, 1, 35-8.
51. Zhao Z, Liu J, Li S, et al (2009). Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia. Prostate, 69, 1292-302.
52. Zhaozhan T, Zhou Y (2002). Observation of 104 cases of precancerous lesions from the prostate resected specimens. Henan J Oncol, 15, 51-2.
53. Zou L, Zhang PG, Zou S, et al (2002). The half-life of cytosolic thymidine kinase in serum by ECL dot bolt potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biolog Marker, 17, 135-40.